导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -8.93% | 3679/4773 |
| 近一周 | -2.43% | 2138/5462 |
| 近一月 | -1.28% | 898/5421 |
| 近一季 | -2.05% | 1150/5209 |
| 近半年 | -11.75% | 3742/4920 |
| 近一年 | -14.28% | 3639/4366 |
| 近两年 | 4.74% | 2835/2954 |
| 近三年 | -5.02% | 1989/2253 |
| 成立以来 | -49.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.44% 1804/4961 |
-12.22% 4385/5312 |
- - |
- - |
| 2025 | -6.25% 3378/4813 |
-6.80% 3399/3635 |
2.46% 1555/4076 |
2.60% 3787/4524 |
-4.31% 3435/4813 |
| 2024 | 19.30% 533/3463 |
8.08% 202/2808 |
0.45% 606/3014 |
8.61% 2736/3129 |
1.18% 1108/3463 |
| 2023 | 0.98% 378/2656 |
10.64% 363/2280 |
4.58% 80/2385 |
-5.94% 1401/2515 |
-7.22% 2088/2655 |
| 2022 | -7.85% 149/2207 |
-5.38% 188/1919 |
-0.10% 1594/2016 |
-8.03% 164/2113 |
6.00% 399/2208 |
| 2021 | 7.01% 505/1822 |
3.39% 179/1255 |
-3.37% 1242/1330 |
3.39% 406/1466 |
3.59% 418/1822 |
| 2020 | -7.03% 984/1250 |
-6.22% 469/1028 |
-4.05% 1041/1067 |
3.01% 996/1164 |
0.31% 1060/1184 |
| 2019 | 4.80% 779/1092 |
16.57% 668/754 |
-11.03% 756/804 |
-2.66% 709/850 |
3.82% 828/918 |
| 2018 | -24.46% 325/834 |
- - |
- - |
- - |
-5.24% 31/691 |
| 2017 | -5.65% 512/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.85% 331/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证高铁产业指数(LOF) VS. 长安沪深300非周期A(740101) |